AI-powered earnings and news diagnosis. Updated regularly.
Merck is a large, established drugmaker with modest revenue growth, but earnings dropped nearly 20% year-over-year. The stock trades at a premium P/E of 32, suggesting investors expect a turnaround. It's a stable but currently pressured name.
Read full analysis →